How Can We Protect Bacteriophages Without Trapping Them? Mathematics May Hold the Key to More Effective Oral Phage Therapy

For more than a century, bacteriophages have fascinated microbiologists because of their remarkable ability to infect and eliminate bacteria with extraordinary specificity. Today, their renaissance is being driven by the global antimicrobial resistance crisis, yet one of the greatest challenges facing phage therapy has surprisingly little to do with virology itself. Even the most potent therapeutic phage becomes ineffective if it cannot survive long enough to reach the infection. This is particularly true for oral administration, where bacteriophages must first pass through the highly acidic gastric environment before reaching the intestine, a journey that destroys a substantial proportion of viral particles before they ever encounter their bacterial host. Protecting phages from this hostile environment has therefore become one of the major engineering problems in modern phage therapy.

Encapsulation has emerged as one of the most promising solutions. Instead of administering free phage particles, researchers embed them within microscopic biodegradable capsules composed of polymers such as alginate, chitosan or other biocompatible materials. These capsules act as temporary physical barriers that shield phages against gastric acidity, digestive enzymes, bile salts and mechanical stress while allowing them to be gradually released further along the gastrointestinal tract. Numerous experimental studies have demonstrated that encapsulation dramatically improves phage survival under simulated gastric conditions, often preserving infectious particles that would otherwise be completely inactivated within minutes at low pH.

Yet this apparently straightforward solution creates an unexpected biological paradox. A bacteriophage enclosed inside a protective capsule is simultaneously protected and biologically inactive. While trapped within the carrier, it cannot adsorb onto bacterial receptors, inject its genome or begin its lytic replication cycle. The very mechanism designed to preserve therapeutic activity therefore temporarily prevents that activity from occurring. Designing an efficient encapsulation system consequently requires solving a delicate optimisation problem rather than simply building the strongest possible capsule.

This challenge is the focus of a new study by Sílvia Cuadrado, Carles Barril and Xavier Bardina, published in Mathematical Methods in the Applied Sciences. Rather than approaching the problem experimentally, the authors developed a mathematical framework capable of describing the dynamics of encapsulated bacteriophages as they travel through the gastrointestinal tract. Their objective was not to recommend a specific pharmaceutical formulation but to determine the theoretical conditions under which encapsulation genuinely improves therapeutic efficacy and when it may instead reduce it.

The model is built upon systems of differential equations describing three interacting populations: bacteria, free bacteriophages and encapsulated bacteriophages. Unlike many previous mathematical descriptions of phage therapy, the model explicitly incorporates the gradual release of viruses from protective microcapsules while simultaneously accounting for phage degradation during gastrointestinal transit. This seemingly modest addition fundamentally changes the therapeutic dynamics because phage availability becomes a time-dependent process rather than an instantaneous event.

One of the most important conceptual advances introduced by the study is the distinction between the administered phage dose and the effective phage dose. In conventional pharmacology these two quantities are often closely related, but for encapsulated phages they may differ substantially. Millions or even billions of viral particles can be administered orally, yet only a fraction ultimately survives gastric passage, escapes the capsules and remains infectious when reaching the target tissue. The therapeutic question is therefore no longer how many phages are delivered to the patient, but how many biologically active phages actually become available to infect bacteria at the right time and in the right location.

To investigate this question, the researchers compared two biological scenarios. In the simplest model, phages are assumed to be administered directly into the compartment where bacteria are already present. Under these conditions encapsulation provides little benefit. Because phages already occupy the infection site, delaying their release simply reduces the number of viruses immediately available for bacterial infection. The effective dose never exceeds the administered dose, and encapsulation merely introduces unnecessary latency into the therapeutic process.

The situation changes dramatically once the model includes two biological compartments corresponding, for example, to passage from the stomach into the intestine. Here, bacteriophages experience continuous degradation while travelling through the first compartment before reaching their bacterial targets in the second. Under these circumstances encapsulation becomes advantageous because the improved survival during transit more than compensates for the delayed release. Mathematical optimisation identifies combinations of capsule permeability and administration frequency that maximise the number of viable phages reaching the infection site. Rather than simply delaying therapy, appropriately designed encapsulation increases the effective therapeutic dose available where it matters most.

The results illustrate a fundamental principle that extends beyond phage therapy itself. Drug delivery systems are rarely judged solely by the quantity of drug administered; instead, they are evaluated according to how efficiently they deliver active molecules to their biological target. Phage therapy follows exactly the same logic, except that its therapeutic agents are self-replicating biological entities whose success depends on encountering susceptible bacterial hosts before losing infectivity.

The model also provides insights that are extremely difficult to obtain experimentally. Laboratory studies can measure phage titres before and after simulated digestion, but they cannot easily explore thousands of different combinations of capsule permeability, release kinetics, degradation rates, administration intervals and bacterial growth dynamics. Computational modelling allows researchers to investigate these parameters systematically before committing to expensive in vitro or animal experiments.

Among the variables explored, capsule permeability emerges as one of the most influential. Highly permeable capsules release phages rapidly but offer relatively poor protection against gastric acidity. Conversely, highly protective capsules preserve viral particles during transit but may delay release long enough to reduce therapeutic benefit. Between these extremes lies an optimal balance in which sufficient protection is maintained while allowing timely bacterial infection. Identifying this balance experimentally would require an enormous number of formulation studies, whereas the mathematical framework rapidly narrows the parameter space to the most promising candidates.

These conclusions closely align with recent experimental observations. Modern encapsulation technologies based on sodium alginate, chitosan and other biodegradable polymers consistently demonstrate improved phage survival under highly acidic conditions while maintaining efficient release in simulated intestinal environments. Several studies have reported encapsulation efficiencies exceeding 95%, substantial improvements in gastric stability and prolonged storage without major losses in infectivity, supporting the biological assumptions underlying the mathematical model.

The implications extend far beyond intestinal infections. Controlled-release systems are increasingly being investigated for pulmonary delivery, chronic wound management, urinary tract infections, implant-associated biofilms and veterinary medicine. Every one of these applications faces the same fundamental engineering question: how can therapeutic phages be protected during delivery while remaining immediately available once they reach their bacterial target? Although each anatomical site presents distinct physiological constraints, the underlying optimisation problem remains remarkably similar.

Future generations of encapsulated phage therapies may become even more sophisticated. Rather than relying solely on passive diffusion or gradual capsule degradation, researchers are already exploring biomaterials capable of responding to local environmental signals such as pH changes, bacterial enzymes, inflammatory mediators or specific metabolites. Such "smart" delivery systems could release phages precisely when they encounter an infection, further increasing therapeutic precision while reducing unnecessary viral exposure.

The authors emphasise that their mathematical framework should not be viewed as a clinical guideline but as a decision-support tool capable of directing future experimental research. They propose validating their predictions using interconnected bioreactor systems reproducing the different physiological compartments of the gastrointestinal tract before progressing towards biological and clinical studies. Additional developments may incorporate stochastic effects describing small viral populations, alternative release mechanisms or multiple interconnected compartments representing increasingly realistic physiological conditions.

This work also reflects a broader transformation occurring throughout biomedical science. Mathematical models are no longer merely used to interpret experimental observations after they have been generated. Increasingly, they guide experimental design, optimise therapeutic strategies and predict biological behaviour before laboratory work even begins. As phage therapy continues to evolve from experimental concept to clinical reality, integrating microbiology, biomaterials, pharmacology and quantitative mathematics may become just as important as discovering new bacteriophages themselves.

Ultimately, the central question addressed by this study is deceptively simple: how can bacteriophages be protected without preventing them from doing the very job they were designed to perform? The answer is unlikely to emerge from microbiology alone. Instead, it appears increasingly clear that the future of oral phage therapy will depend on an interdisciplinary dialogue between virology, pharmaceutical engineering and applied mathematics, where equations become as important as Petri dishes in shaping the next generation of antibacterial therapeutics.

Source :

Cuadrado S., Barril C., Bardina X. Dynamics of Encapsulated Bacteriophage in the Gastrointestinal Tract. Mathematical Methods in the Applied Sciences. https://doi.org/10.1002/mma.70342